Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Arno Therapeutics and Leica Biosystems Enters into a Co-development Agreement

Published: Wednesday, January 08, 2014
Last Updated: Wednesday, January 08, 2014
Bookmark and Share
Test for detection of activated form of progesterone receptor (APR) in men's and women's cancers.

Arno Therapeutics, Inc. and Leica Biosystems (LBS) have announced that the companies have entered into a co-development agreement for the development of a companion diagnostic (CDx) for Arno's lead compound and personalized therapy, onapristone.

Onapristone is an oral, anti-progestin hormone blocker that has been shown to have anti-tumor activity in breast cancer. Onapristone appears to selectively block the activation of the progesterone receptor (APR). This is believed to inhibit the growth of APR-driven breast, endometrial and other tumors.

The CDx will be an immunohistochemical (IHC) in vitro diagnostic (IVD) test used to detect APR in various women's cancers, including endometrioid and breast cancer. This CDx test will help to identify patients who are APR positive and therefore most likely to respond to treatment with onapristone. This also has potential application in castration-resistant prostate cancer (CRPC).

In preclinical work sponsored by Arno, IHC testing on archived specimens has shown that approximately 40% of archived endometrioid cancer specimens and approximately 25% of archived breast cancer specimens were APR positive.

Initial findings by Arno indicate that progesterone receptor (PR) was present in CRPC specimens and potentially active in a subset of tumors. Further investigation is underway to determine the frequency of APR positive tumors in CRPC specimens.

Under the terms of the co-development agreement, Arno will sponsor and conduct clinical trials for onapristone. Leica will develop and validate the CDx for APR with responsibility for ensuring the investigational CDx kit is ready, available and meets FDA and other health authority standards for a planned Phase II trial of onapristone in endometrioid cancer. The co-development program aims to achieve simultaneous approval and launch of onapristone and the CDx IVD for APR.

"This agreement with Leica Biosystems is a significant milestone for Arno and an important step forward in the development of onapristone. We believe that partnering with a world-class organization such as Leica will enable us to quickly and effectively get to reliable, reproducible and practical APR positive tumor detection. This will help identify the patients most likely to benefit from treatment with onapristone," said Glenn Mattes, Chief Executive Officer of Arno Therapeutics. "We are excited about what the future holds for Arno as we enter a critical period for the Company with the commencement of our first Phase I trial which will evaluate onapristone in progesterone receptor positive tumors."

"We are pleased to partner with Arno to co-develop this companion diagnostic for onapristone," added Dr. Matthias Weber, President of Leica Biosystems. "Personalized medicine is a key development in oncology. We believe that diagnostics such as the APR test will play a critical role in the broader effort to improve quality of care for patients."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
Heart Defect Prediction Technology Could Lead to Earlier, More Informed Treatment
Experimental method uses genetics-guided biomechanics, patient-specific stem cells.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Fast, Simple Test for Colitis
A minimally invasive screening for ulcerative colitis using emerging infrared technology could be a rapid and cost-effective method for detecting disease that eliminates the need for biopsies and intrusive testing of the human body.
Scans Reveal Babies of Mothers with Gestational Diabetes Have More Body Fat
Researchers at Imperial College London have found that the babies born to mothers with gestational diabetes have more body fat at two months of age compared to babies born to healthy mothers.
New Device Could Improve Cancer Detection
UBC researchers develop a microfluidic device to capture circulating tumor cells.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!